Compare JJSF & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JJSF | RVPH |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 71.0M |
| IPO Year | N/A | N/A |
| Metric | JJSF | RVPH |
|---|---|---|
| Price | $93.59 | $0.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $138.33 | $3.33 |
| AVG Volume (30 Days) | 319.1K | ★ 4.3M |
| Earning Date | 11-17-2025 | 11-13-2025 |
| Dividend Yield | ★ 3.41% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.36 | N/A |
| Revenue | ★ $3,166,466,000.00 | N/A |
| Revenue This Year | $4.28 | N/A |
| Revenue Next Year | $2.24 | N/A |
| P/E Ratio | $27.90 | ★ N/A |
| Revenue Growth | ★ 0.54 | N/A |
| 52 Week Low | $80.67 | $0.25 |
| 52 Week High | $170.77 | $2.95 |
| Indicator | JJSF | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 60.62 | 58.18 |
| Support Level | $89.94 | $0.60 |
| Resistance Level | $94.05 | $0.77 |
| Average True Range (ATR) | 2.30 | 0.05 |
| MACD | 0.45 | 0.01 |
| Stochastic Oscillator | 90.95 | 61.01 |
J&J Snack Foods Corp. manufactures snack foods and distributes frozen beverages, which it markets nationally to the foodservice and retail supermarket industries. The company's portfolio of frozen beverages, frozen novelties, and baked goods includes soft pretzels, frozen juice treats and desserts, stuffed sandwiches, churros, funnel cakes, cookies, and other snack foods and drinks. It operates through three segments: Food Service, which sells snacks, desserts, and baked goods at the point of sale; Retail Supermarkets, which sells frozen and prepackaged products to supermarkets; and Frozen Beverages, which sells frozen beverages under the ICEE, Slush Puppie, and Parrot Ice brands in the United States, Mexico, and Canada. The majority of revenue comes from the Food Service segment.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.